Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels
of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated
endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from
cortisol overproduction by the adrenal glands is the subject of this protocol.
Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic
administration of high doses of glucocorticoids, were not eligible for enrollment in this
study.
The purpose of this study was to evaluate the safety and efficacy of CORT125134 for treatment
of endogenous Cushing's syndrome. The multicenter study was conducted in the United States
and in Europe.